The European Union’s medicines agency has stated that there is “no indication” that Oxford-AstraZeneca’s coronavirus vaccine is the cause of reported blood clots, which has caused a vast amount of European countries to temporarily suspend the rollout of one of the four COVID-19 vaccines currently authorised in the EU.
EMA Executive Director Emer Cooke said that the Agency has been carrying out a case-by-case evaluation of incidents and was expected to complete its review today.
Ms Coke said: “I want to also stress that at present, there is no indication that vaccination has caused these conditions (blood clots). They had not come up in the clinical trials, and they are not listed as known or expected side events with this vaccine.”
She said that in fact in clinical trials, both the vaccinated people and the people who received the placebo had shown some very small numbers of blood clot developments.
She added: “The number of thromboembolic events in the vaccinated people, overall, seems not to be higher than that seen in the general population.”
The EMA has said “many thousands of people” in the European Union develop blood clots every year and “the number of thromboembolic events overall in vaccinated people seems not to be higher than that seen in the general population”.